A study of the Oxidative stress and Antioxidant status in diabetic subjects who are on treatment with Metformin
Main Article Content
Abstract
Background: Oxidative stress plays an important role in the pathogenesis of DM and its complications. However, antioxidant status and its contribution to type 2 DM are less explored in South Indian population. Metformin, is a biguanide anti hyperglycemic agent used for the management of type 2 diabetes. Aim:Â To study the alteration in oxidant and antioxidant status in type 2 diabetic subjects on treatment with Metformin and to evaluate the effect of metformin in improving the total antioxidant status. Methodology: In this cross sectional study, all subjects were T2DM patients, on metformin monotherapy (500 mg, bd) and were grouped into two - Group 1 and Group 2 for the study purpose, based on their HbA1c values. Baseline parameters (B.P, Waist Hip ratio, BMI, family history), glycemic status, lipid profile, FRAP, TBARS and serum Metformin levels were assayed. Fasting and postprandial blood specimens were collected and plasma glucose concentrations were measured by standard methods. Fasting plasma total antioxidant capacity (TAC) was measured by ferric reducing ability of plasma (FRAP) assay. Oxidative stress was evaluated and measured as TBARS and the values were compared among the two groups. Results: TBARS levels were higher and FRAP levels were significantly lower in Group I subjects compared to Group II subjects and can be explained due to increased superoxide ions and reduced activity of S. O. D. Conclusion: It may be concluded that total antioxidant status is lower in type 2 diabetic subjects of Group 1 category compared to diabetic subjects in the Group 2 and it may be related to the beneficial effects of the biguanide, Metformin.
Article Details
Section
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
References
International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium, International Diabetes Federation. 2012.
International Diabetes Federation. Country estimates table 2011. IDF diabetes atlas. 6th Ed. 2012.
Akbar S, Bellary S, Griffiths HR (2011) Dietary antioxidant interventions in type 2 diabetes patients: a meta-analysis. British Journal of Diabetes & Vascular Disease 11: 62-68.
Chang Y, Chuang L (2010). The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res 2: 316-331?
Noori S. An Overview of Oxidative Stress and Antioxidant Defensive System. 2012; 1:413.
Van Campenhout A, Van Campenhout C, Lagrou AR. Impact of diabetes mellitus on the relationships between iron-, inflammatory and oxidative stress status. Diabetes Metab Res Rev. 2006; 22: 444 – 454.
Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104:517–29. 8.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stressactivated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003; 52:1-8. 9.
Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, Matsuhisa M, Yamasaki Y. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007; 9:355-66].
Benzie IF. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int J Food Sci Nutr. 1996;47(3):233-61
Stocker R and Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004; 84:1381-1478.
Bennie IFF and Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power†the FRAP assay. Anal Biochem.1996; 239:70-76.
Kazimirova A, Barancokova M, Volkovova ,Staruchova M, Krajcovicova-Kudlackova M, Wsolova L, Collins AR and Dusinska M. Does a vegetarian diet influence genomic stability? Eur J Nutr. 2004; 43:32-38.
Choi SW, Benzie IF, Collins AR, Hannigan M and Strain JJ.Vitamins C and E: acute interactive effects on biomarkers of antioxidant defence and oxidative stress. Mutat Res. 2004; 551:109-117.
Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes its Complications. 2001; 15: 203-210.
Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Perspectives in Diabetes. Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection. Diabetes. 2003; 52: 581-587.
Bigali E, Raimondi L, Mannuci E, Colombi C, Bardini G, Rotella CM, Lodovici M. Lipid and protein oxidation products, antioxidant status and vascular complications in poorly controlled type 2 diabetes. Br J Diabetes Vasc Disc. 2011; 12: 33-39.
Milech A, Oliveira JEP, Vencio S, organizadores. Diretrizes da Sociedade Brasileira de Diabetes (2015-2016). São Paulo: A.C. Farmacêutica; 2016
Bellin C, Wiza DH, Wiernsperger NF, Rösen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res. 2006 Nov; 38(11):732-9]
Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL JAMA. 1994 Jul 20; 272(3):205-11.
King H, Aubert RE, Herman WH. Global Burden of Diabetes, prevalence, numerical estimates & projections. Diabetes Care. 1998; 21: 1414-31.
Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care.1999; 22:908 -12.
Moussa SA. Oxidative stress in diabetes mellitus. Romanian J Biophys 2008; 18: 225-336.
McCordJM. The evolution of free radicals andoxidative stress. Am J Med 2000; 108:650-9Taylor AE et al., 1986
Suyama FD. Patobiologi radikal bebas. Makalah symposium peranan radikal hebas dan antioksidan pada sejumlah penyakit. Jakarta; 27 Januari 2001. b.8-14.
Matsuda M, DeFronzo RA. In vivo measurement of insulin sensitivity in humans. In Clinical Research in Diabetes and Obesity. Draznin B, Rizza R, Eds. Totowa, NJ, Humana. 1997; 1: 23-65.
Siddique MAH, Tamannaa Z, Kamaluddin SM, Saiedullah M, Khan MAH, et al. (2016) Total antioxidant status in newly-diagnosed type II diabetes patients in Bangladeshi population. J Mol Pathophysiol 5: 5-9.
Abdulkadir, Thanoon IA (2012) Comparative Effects of Glibenclamide and Metformin onC-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus. Sultan QaboosUniv Med J 12: 55-61.
Pavlovic D, Kocic R, Kocic G, Jevtovic T, Radenkovic S, et al. (2000) Effect of four week metforminTreatmenton plasma and erythrocyte antioxidative defense enzymes in newlydiagnosed obese patients with type 2 diabetes. Diabetes ObesMetab 2: 251-256.
Skrha J, Prazny M, Hilgertova J, Kvasnicka J, Kalousova M, et al. (2007) Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol63: 1107-1114.
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
Soliman GZA (2008) Blood lipid peroxidation (superoxide dismutase, malondialdohyde, glutatione) level in Egyptian type 2 diabetic patients. Singapore Med J 49: 129-136.
Reaven G (1996) Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. Diabetes mellitus: a fundamental and clinical text Philadelphia. Circulation93: 1780-1783.
Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care. 1998; 21:1470 -74.
Cabrales P, Salazar Vázquez MA, Salazar Vázquez B, RodrÃguez- Morán M, Intaglietta M, Guerrero-Romeros F. Blood pressure reduction due to hemoglobin glycosylation in type 2 diabetic patients. Vasc Heal Risk Manag 2008; 4: 917-922.
Kumawat M, Pahwa MB, Gahlaut VS, Singh N. Status of antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus with micro vascular complications. Open Endocrinol J 2009; 3: 12-15
Mahboob M, Rahman MF, Grover P. Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. Singapore Med J 2005; 46:322-4.
Sekeroglu MR, Sahin H, Dulger H, et al. The effect of dietary treatment on erythrocyte lipid peroxidation, superoxide dismutase, glutathione peroxidase, and serum lipid peroxidation in patients with type 2 diabetes mellitus. Clin Biochem.2000; 33:669-74.
Harris ED. Regulation of antioxidant enzymes. FASEB J.1992; 6:2675-83.
Slatter, Bolton DA, Bailey CA, et al. The importance of lipid-derived malondialdehyde in diabetes mellitus [Review]. Diabetologia. 2000; 43: 550-7.
Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants. A review. J Biochem Mol Toxicol. 2003; 17: 24-38.
Maura Lodovici, Lisa Giovannelli, Vanessa Pitozzi , Elisabetta Bigagli , Gianluca Bardini, Carlo Maria Rotella. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control Mutation Research. 2008; 638:98-102.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev.2002; 23:599-622.
Tan HH, Tan HK, Lim HS, Tana AS, Lim SC. Gestational diabetes mellitus: a call for systematic tracing. Ann. Acad. Med. Singapore.2002; 31:281-84.
Bonora E, Corraro G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, et al. Prevalence and correlates of post – prandial hyperglycemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2000; 49:846-54.
Carroll M,Izard A, Riboni K, Burge MR, Schade DS. Fasting hyperglycemia predicts the magnitude of postprandial hyperglycemia. Diabetes Care 2002; 25: 1247-8.